CLINICAL TRIALS PROFILE FOR EPACADOSTAT

Clinical Trials for Epacadostat

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01604889 ↗	A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma	Terminated	Incyte Corporation	Phase 1/Phase 2	The study design includes an open-label, dose escalation phase followed by a blinded, randomized phase, which combines epacadostat (an oral IDO1 inhibitor) with an approved therapy and compares to approved therapy plus placebo in metastatic melanoma patients.
NCT01685255 ↗	A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy	Terminated	Incyte Corporation	Phase 2	This is an open-label, randomized, phase 2 study of an IDO inhibitor, INCB024360 (epacadostat) versus tamoxifen in biochemical recurrent only ovarian cancer patients following complete remission with first-line chemotherapy.
NCT01961115 ↗	Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma	Completed	Incyte Corporation	Phase 2	This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens may help the body build an effective immune response to kill tumor cells. Giving epacadostat with vaccine therapy may be an effective treatment for advanced melanoma.
NCT01961115 ↗	Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma	Completed	National Cancer Institute (NCI)	Phase 2	This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens may help the body build an effective immune response to kill tumor cells. Giving epacadostat with vaccine therapy may be an effective treatment for advanced melanoma.
NCT01961115 ↗	Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma	Completed	University of Virginia	Phase 2	This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens may help the body build an effective immune response to kill tumor cells. Giving epacadostat with vaccine therapy may be an effective treatment for advanced melanoma.

Clinical Trial Conditions for Epacadostat

Condition Name

Condition Name
Intervention	Trials
Head and Neck Cancer	6
Lung Cancer	5
Solid Tumors	5
Advanced Solid Tumors	4

Condition MeSH

Condition MeSH
Intervention	Trials
Carcinoma	17
Neoplasms	10
Carcinoma, Non-Small-Cell Lung	9
Head and Neck Neoplasms	8

Clinical Trial Locations for Epacadostat

Trials by Country

Trials by Country
Location	Trials
United States	316
Japan	45
Canada	31
Australia	24
United Kingdom	16

Trials by US State

Trials by US State
Location	Trials
California	29
New York	17
Pennsylvania	17
Illinois	17
Texas	16

Clinical Trial Progress for Epacadostat

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	7
Phase 2	24
Phase 1/Phase 2	15

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	14
Terminated	12
Withdrawn	12

Clinical Trial Sponsors for Epacadostat

Sponsor Name

Sponsor Name
Sponsor	Trials
Incyte Corporation	35
Merck Sharp & Dohme Corp.	14
National Cancer Institute (NCI)	8

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	65
Other	36
NIH	8